On Sept. 29, 2021, VBI Vaccines announced positive results from multiple preclinical studies against several COVID-19 variants of concern as well as the initiation of dosing in the Phase 1b portion of the ongoing clinical study of VBIﾒs SARS-CoV-2 vaccine candidates in approximately 80 adults age 18-54.